Press releases
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
May 3, 2011Radiofrequency ablation catheter designed to treat a variety of arrhythmias
Boston Scientific Corporation (NYSE: BSX) today announced CE Mark approval and first use in Europe of its Blazer™ Open-Irrigated Catheter, the...
-
May 2, 2011
Boston Scientific Corporation (NYSE: BSX) today announced its schedule of major events and sponsored research at the 32nd Annual Scientific Sessions of...
-
Apr 27, 2011
Boston Scientific Corporation (NYSE: BSX) is scheduled to participate in the Bank of America Merrill Lynch 2011 Health Care Conference on May 11 in...
-
Apr 26, 2011
Boston Scientific Corporation (NYSE: BSX) is scheduled to participate in the Deutsche Bank 36th Annual Healthcare Conference on May 2 in Boston. Ray...
-
Apr 25, 2011Innovative alloy designed to improve new coronary stent's acute performance
Boston Scientific Corporation (NYSE: BSX) today announced U.S. Food and Drug Administration (FDA) approval and launch of the ION™ Paclitaxel-Eluting...
-
Apr 20, 2011
Boston Scientific Corporation (NYSE: BSX) today announced financial results for the first quarter ended March 31, 2011, as well as net sales and...
-
Apr 14, 2011
Boston Scientific Corporation (NYSE: BSX) will webcast its conference call discussing financial results for the first quarter ended March 31, 2011 on...
-
Apr 5, 2011Innovative stent designed to treat peripheral vascular lesions for stenoses in arteries above the knee
Boston Scientific Corporation (NYSE: BSX) today announced the start of patient enrollment in the SuperNOVA clinical trial, an international,...
-
Apr 4, 2011Reduction of geographic miss and bail-out stenting observed with highly visible PROMUS Element Stent
Boston Scientific Corporation (NYSE: BSX) today announced 12-month results from the pivotal PLATINUM Workhorse trial comparing the...
-
Apr 3, 2011Lower event rates for new alloy and stent design versus older drug-eluting stent model
Boston Scientific Corporation (NYSE: BSX) today announced results from a pooled patient-level analysis of its PERSEUS and TAXUS ATLAS...
-
Mar 29, 2011Clinical presentations to include 12-month data on PROMUS Element™ Platinum Chromium Stent
Boston Scientific Corporation (NYSE: BSX) today announced its clinical trial news and events schedule at the 60th Annual Scientific Session of the...
-
Mar 24, 2011New technology designed to improve lead anchoring speed and consistency for physicians
Boston Scientific Corporation (NYSE: BSX) today announced U.S. Food and Drug Administration (FDA) approval and U.S. launch of the Clik™ Anchor for...
-
Mar 22, 2011
Boston Scientific Corporation (NYSE: BSX) today announced that it will hold an analyst event on April 4, 2011 at the 60th Annual Scientific Session of...
-
Mar 8, 2011
Boston Scientific Corporation (NYSE: BSX) is scheduled to present at the Barclays Capital 2011 Global Healthcare Conference in Miami. Jeff Capello,...
-
Mar 7, 2011Third-generation bare-metal stent offers improved acute performance in treating patients with coronary artery disease
Boston Scientific Corporation (NYSE: BSX) today announced it has received CE Mark for its OMEGA™ Platinum Chromium Bare-Metal Coronary Stent System,...
-
Mar 3, 2011Company adds innovative technology for atrial fibrillation patients with high stroke risk
Boston Scientific Corporation (NYSE: BSX) today announced the completion of its acquisition of Atritech, Inc. of Plymouth, Minnesota. The completion...
-
Feb 17, 2011Company's third-generation drug-eluting stents now available in rapidly growing market
Boston Scientific Corporation (NYSE: BSX) today announced its launch of the PROMUS® Element™ Everolimus-Eluting Coronary Stent System and TAXUS®...
-
Feb 16, 2011
Boston Scientific Corporation (NYSE: BSX) is scheduled to participate in the 2011 RBC Capital Markets' Healthcare Conference on March 2 in New York....
-
Feb 15, 2011New products expand treatment options for healthcare providers
Boston Scientific Corporation (NYSE: BSX) today announced the acquisition of two novel technologies to treat peripheral chronic total occlusions...
-
Feb 15, 2011Scholarship Fund Honors Company's Late Chief Medical and Scientific Officer
Boston Scientific Corporation (NYSE: BSX) today announced that it has established a $1.7 million endowment to fund the "Donald S. Baim, M.D., '75...
-
Feb 8, 2011
Boston Scientific Corporation (NYSE: BSX) today welcomed the publication of a sub-analysis of the MADIT-CRT trial data in the current issue of the...
-
Feb 3, 2011New system integrates market-leading Renegade HI-FLO Microcatheter with high-torque Fathom-16 Steerable Guidewire for peripheral embolization procedures
Boston Scientific Corporation (NYSE: BSX) today announced the availability of its Renegade® HI-FLO™ Fathom® Pre-Loaded System for selective...
-
Feb 1, 2011
Boston Scientific Corporation (NYSE: BSX) today announced financial results for the fourth quarter and full year ended December 31, 2010, as well as net...
-
Jan 28, 2011
Boston Scientific Corporation (NYSE: BSX) today announced that yesterday afternoon, the Civil Division of the U.S. Department of Justice (DOJ) filed a...
-
Jan 27, 2011Procedure performed as part of BLOCk-CTI clinical trial evaluating treatment of Type 1 atrial flutter
Boston Scientific Corporation (NYSE: BSX) today announced the first use of the Blazer® Open-Irrigated Catheter in the U.S. as part of the BLOCk-CTI...